Positron emission tomography (PET) imaging is a useful method to evaluate in situ estrogen receptor (ER) status for the early diagnosis of breast cancer and optimization of the appropriate treatment strategy. The 18 F-labeled estradiol derivative has been successfully used to clinically assess the ER level of breast cancer. In order to simplify the radiosynthesis process, one-step 18 F-19 F isotope exchange reaction was employed for the 18 F-fluorination of the tracer of [ 18 F]AmBF 3 -TEG-ES. The radiotracer was obtained with the radiochemical yield (RCY) of ∼61% and the radiochemical purity (RCP) of >98% within 40 min. Cell uptake and blocking assays indicated that the tracer could selectively accumulate in the ER-positive human breast cancer cell lines MCF-7 and T47D. In vivo PET imaging on the MCF-7 tumor-bearing mice showed relatively high tumor uptake (1.4∼2.3 %D/g) and tumor/muscle uptake ratio (4∼6). These results indicated that the tracer is a promising PET imaging agent for ER-positive breast cancers.
Introduction
Breast cancer has become the most common malignancy in women and the incidence of breast cancer is increasing over the world [1] . One of the primary reasons that cause death from breast cancer may be due to the lack of effective early diagnosis method [1] . Therefore, development of novel effective early diagnosis methods is critical for the treatment and survival of patients with breast cancer. It is acknowledged that estrogen plays an important role in the initiation and progression of breast cancer [2, 3] . The stimulatory effect of estrogen is mediated by nuclear estrogen receptors (ERs) [4] . Therefore, the estrogen receptor can serve as an important predictive biomarker of breast cancers [5] . The understanding of ER level is also essential for prognosis and optimization of the treatment strategy. The ER-positive (ER + ) tumors often respond to the hormonal therapy, whereas the ER-negative (ER − ) tumors usually require the surgical and chemotherapeutic interventions [2, 6, 7] .
Positron emission tomography (PET) as an efficient noninvasive imaging technology has been applied successfully in clinic to provide the possibility for assessing the entire lesion and highly sensitive images of cancer diseases. Fluorine-18 is the most widely used radioisotope because of its ideal nuclear properties, such as low positron energy (0.64 MeV) and suitable physical half-life (109.8 min). Some fluorine-18-labeled estradiol derivatives, such as 16 -[
18 F]fluoroestradiol ([
F]FES) and C3-7 -[
18 F]FES, have been studied in preclinical evaluation, and tumor uptakes in PET imaging studies show a good correlation with the ER expression levels [7, 8] . However, the preparation of these radiotracers always require multisteps, including at least one drying step and semi-prep high performance liquid chromatography (HPLC) purification step. This will increase the risk of radiosynthesis failure and reduce the radiochemical yield (RCY) of radiotracer [9] . The multistep procedures are also challenged by the relatively short half-life of the radioisotope fluorine-18 [10] . Therefore, simplification of the radiosynthesis process is essential for the development and application of PET tracers based on the estradiol derivatives.
Recently, Liu and coworkers have developed a one-step 18 F-labeling method with high radiochemical yield and high 2 Contrast Media & Molecular Imaging specific activity [9] . The 18 F-labeling can be realized by the simple 18 F-19 F isotope exchange reaction on an ammoniomethyl-trifluoroborate (AmBF 3 ) group without further drying of fluoride-18 ion and HPLC purification. Compared with other multistep radiolabeling methods, the one-step 18 F-labeling approach is much more practical for clinical applications. However, this method is still not used widely to prepare PET imaging agents [11] and even no studies using this method to develop tracers of estradiol derivatives were reported.
Encouraged by the previous studies [11] , in the present work we attempt to develop a novel estradiol-based PET tracer for imaging the ER-positive breast cancers by using the one-step 18 F-labeling method to simplify the radiosynthesis procedure. The new tracer [ 18 F]AmBF 3 -TEG-ES was prepared by conjugation of AmBF 3 and estradiol with a PEG 4 spacer. This new tracer could be easily prepared through onestep 18 F-labeling method and simple purification in a short time. The in vitro stability, cytotoxicity, lipophilicity, and tumor cell uptake of the radiotracer were also investigated systematically. In addition, in vivo micro-PET imaging of breast cancer-bearing mice was also carried out and the results indicated that the tracer [
18 F]AmBF 3 -TEG-ES would be a potential PET imaging agent for the diagnosis of estrogen-dependent tumors.
Materials and Methods

General.
All the materials were purchased from Energy Chemical and were all of reagent grade or analytical grade without further purification. Flouride-18 was obtained from a medical cyclotron (HM7, Sumitomo Heavy Industries) through a bombardment of 18 O-enriched water. Human breast cancer cell lines T47D and MCF-7 were purchased from the Cell Bank of Chinese Academy of Sciences (Shanghai, China) and cultured in the 1640 medium and -MEM medium (Biological Industries, Israel) with 10% (v/v) fetal bovine serum (Biological Industries, Israel) in a 37 ∘ C incubator under 5% CO 2 , respectively. A 1470 Wizard counter (Perkin-Elmer Corporation, USA) was employed in the studies of cellular uptake.
The semi-prep HPLC (Waters, USA) with a Waters 2998 photodiode array detector (PDA) and C18 HPLC column (5 m, 250 × 19 mm, Phenomenex) was employed for purification of compounds. The flow rate of semi-prep HPLC was 3 mL/min. The semi-prep HPLC method for the purification of AmBF 3 -TEG-ES has been listed in Table 1 .
The analytical HPLC equipped with a C18 column (5 m, 250 × 4.6 mm, Phenomenex) and a Waters 2487 dual absorbance detector was used for purity identification of the precursor on a Waters Breeze system. A Radiomatic 610TR flow scintillation analyzer (Perkin-Elmer) was necessary for the quality control analysis of radiolabeled compounds in this system. The flow rate of analytical HPLC was 1 mL/min. The analytical HPLC method for quality control has been listed in Table 2 .
Animals. BALB/c nude mice (18-20 g; 4-6 weeks old; SLAC Laboratory Animal Co. Ltd., Shanghai, China) were used for animal experiments. Mice were housed with free access to food and water and allowed ample time to acclimatize before the experiments. The tumor-bearing mice were established by subcutaneous injection of MCF-7 cells (5 × 10 6 ) suspended in PBS (100 L) in the right shoulder of each nude mouse. The tumors were allowed to grow for around 3-4 weeks to reach the size of 0.5-1.0 cm in diameter for in vivo studies. All procedures and animal protocols were approved by the Animal Care and Ethnics Committee of Jiangsu Institute of Nuclear Medicine.
Nuclear magnetic resonance spectrometers ( 1 H-NMR, 13 C-NMR, and 19 F-NMR, Bruker DRX-400, Bruker, Germany) were used to obtain spectra of samples dissolved in d 6 -DMSO, and the chemical shifts were referenced to tetramethylsilane (TMS). Electrospray ionization mass spectrometry (ESI-MS) was obtained on a Waters Platform ZMD4000 quadrupole tandem mass spectrometer. A Perkin-Elmer 240C Elemental Analyzer was employed for the elemental analysis (C, H, and N). FT-IR spectra of the cold compound AmBF 3 -TEG-ES was obtained using a FT-IR spectrometer (TENSOR27, Bruker) in the range of 400-4000 cm −1 . 
Chemical Synthesis
Synthesis of Compound 4.
The suspension of compound 3 (3.20 g, 8.6 mmol), N,N-dimethylethanolamine (772 L, 7.5 mmol), and KOH (1.62 g, 29 mmol) in THF (50 mL) was refluxed at 70 ∘ C for 12 h. The reaction mixture was filtered and the filtrate was collected. The solvent was evaporated under reduced pressure and then H 2 O (50 mL) was added and extracted with CH 2 Cl 2 (3 × 50 mL). The combined organic layer was dried over hydrous sodium sulfate and then evaporated under reduced pressure. The crude product was purified through flash column chromatography CH 
Stability of AmBF 3 -TEG-ES.
The stability of the cold compound AmBF 3 -TEG-ES was studied in pyridazine-HCl buffer (1.0 M, pH 2.0-2.5) at different temperatures. Briefly, AmBF 3 -TEG-ES was dissolved in pyridazine-HCl buffer and then incubated at various temperature (50, 60, 70, 80, 90, or 100 ∘ C) for 30 min, respectively. After incubation, a little sample was taken out for stability assay using HPLC analysis (Table 1) .
Cytotoxicity Assay of AmBF 3 -TEG-ES.
Traditional 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to assess the cytotoxicity of AmBF 3 -TEG-ES against ER + human breast cancer cell lines T47D and MCF-7. Briefly, the cells were seeded into 96-well plates with 100 L medium at a density of 5 × 10 3 cells per well. Then the cells were incubated in a 37 ∘ C incubator with 5% CO 2 for 12 h. Subsequently, the medium in each well was replaced by different concentrations (12.5, 25, 50, and 100 M) of the cold compound AmBF 3 -TEG-ES (200 L/well), which were diluted with the culture medium. Then, the plates were incubated for 3, 6, 12, and 24 h, respectively. After treatment with AmBF 3 -TEG-ES, MTT solution (20 L, 5 mg/mL) was added to each well and all the plates were incubated for another 4 h. After that, medium in each well was removed and replaced by DMSO (150 L). After the culture plates were shaken for 10 min, the optical density (OD) values were measured on a microplate reader (BioTek Instruments, Inc. Vermont, USA) at 490 nm. All tests were carried out in 6 repeats for at least three independent experiments. 
Radiosynthesis of [
18 F]AmBF 3 -TEG-ES. Fluoride-18 (100-300 mCi) produced by cyclotron was trapped on an anion-exchange resin and then eluted with pyridazine-HCl buffer (200 L) into the reaction polypropylene tube. The precursor AmBF 3 -TEG-ES (10 L, 25 mM in pyridazineHCl buffer) was added to the tube. Then the mixture was heated at different temperature for 30 min, respectively. After reaction, the reaction mixture was loaded on a C18 light cartridge when diluted with water (10 mL). Then, the C18 light cartridge was washed with water (3 × 10 mL). The pure tracer [
18 F]AmBF 3 -TEG-ES was obtained after being eluted with ethanol/saline (0.5 mL) into a glass vial. The target product [
18 F]AmBF 3 -TEG-ES should be diluted with saline for further biological evaluation. A small sample was taken out for radio-HPLC analysis using the condition listed in Table 2 .
Determination of Octanol-Water Partition Coefficient.
Octanol (50 mL) and distilled water (50 mL, pH 7.0) were mixed by oscillation at 25 ∘ C for 24 h. After standing, a separatory funnel was used to separate the two layers. The tracer (30 Ci) in distilled water (500 L) was added to a polypropylene tube. Octanol (500 L) was also added to the tube and then oscillated on a vortex mixer for 5 min. Next, the tube was centrifuged for 5 min at 4000 g to separate the two layers. In each layer, the radioactivity of samples (100 L) in triplicate was measured by a -counter. The partition coefficient (log ) value was calculated using the equation log = log( / ), where is the radioactivity of the tracer in the n-octanol layer and is the radioactivity in the water layer. The result was the average of three independent experiments. 
Cell Uptake and Block Studies of
-TEG-ES (0.5 Ci). The plates were incubated in a 37
∘ C incubator for 15, 30, 60, and 120 min, respectively. For the block study, the cells were pretreated with excess of estradiol for 30 min. At each time point, the supernatant in each well was removed and then the cells were washed with ice-cold PBS (500 L/well) twice. Next, NaOH solution (0.1 M) was added to lyse the cells. The cell lysates were collected and the following eluents of PBS were combined. The radioactivity of cell lysates was determined using a -counter. The cell uptake rate was expressed as the percentage of the total added radioactive dose (%AD).
PET Imaging.
Small animal PET imaging was performed on an Inveon micro-PET scanner (Siemens Medical Solutions, Germany). Imaging studies were carried out on female Balb/c nude mice bearing the human breast cancer cell line MCF-7. The mice were anesthetized with 1.5%-2% isoflurane, positioned prone, immobilized, injected with [ 18 F]AmBF 3 -TEG-ES (150 Ci) via the tail vein, and imaged dynamically for the first hour. Then, static scanning images were collected immediately at 0.5, 1, and 2 h after injection. The obtained images were reconstructed using 3D ordered subset expectation maximization (OSEM 3D/SP-MAP) and then processed using the Siemens Inveon Research Workplace (IRW2.0.0.1050). Regions of interest (ROIs) were drawn over tumors and main organs, and average signal levels in the ROIs were measured. The %ID/g was also calculated. The synthetic route of AmBF 3 -TEG-ES has been shown in Scheme 1. Compound 3 was obtained with high yield by three steps from tetraethylene glycol, which further reacted with N,N -dimethylethanolamine to generate compound 4. And then compound 6 was prepared according to the method by Liu et al. [9, 14] . Finally, AmBF 3 -TEG-ES was obtained through a click reaction of compound 6 and ethinylestradiol. Then the precursor was purified on a semi-prep HPLC with a high yield of 73%. The purity of AmBF 3 -TEG-ES was confirmed by HPLC analysis. As shown in Figure 1 triazole) of 13 C-NMR spectrum as well as the disappearance of alkynyl peaks in the 1 H-NMR and 13 C-NMR spectra demonstrated the successful occurrence of the click reaction ( Figures S2 and S3) . The peak at −75.7 ppm of 19 F-NMR spectrum was assigned to TFA in the final compound and the single peak at −135.5 ppm also indicated the purity of the compound AmBF 3 -TEG-ES ( Figure S4 ). All of these results indicated that the compound AmBF 3 -TEG-ES was successfully synthesized with a high chemical purity.
Results and Discussion
Design and Synthesis of
Stability of AmBF 3 -TEG-ES. Since the one-step
18 F-19 F isotope exchange labeling reaction was performed in the pyridazine-HCl buffer (pH = 2.0-2.5) around 80 ∘ C, the stability of AmBF 3 -TEG-ES in the pyridazine-HCl buffer was studied by HPLC analysis at the temperature range of 50-100 ∘ C. As shown in Figure 2 , the peak at 3.35 min corresponded to the buffer while AmBF 3 -TEG-ES showed a single peak at 16.5 min. After incubation at different temperatures, the HPLC analysis of AmBF 3 -TEG-ES in pyridazine-HCl buffer showed a single peak at 16.5 min. This indicated that AmBF 3 -TEG-ES was stable enough in the pyridazine-HCl buffer after incubation even up to 100 ∘ C for 30 min and the 18 F-labeling reaction can be carried out in the pyridazineHCl buffer.
Cytotoxicity of AmBF 3 -TEG-ES.
The good biocompatibility is essential for the application of a PET imaging agent [15] . Therefore, the cytotoxicity of AmBF 3 -TEG-ES against the human breast cancer cells T47D and MCF-7 was assessed by MTT assay. As can be seen from Figures  3(a) and 3(b) , the cell viability of T47D and MCF-7 did not change significantly after incubation for different time with AmBF 3 -TEG-ES at the concentration ranging from 12.5 to 100 M. In fact, more than 87% of both cells still survived after treatment with AmBF 3 -TEG-ES at the high concentration of 100 M for 24 h. Hence, it is inferred that AmBF 3 -TEG-ES possesses negligible cytotoxicity and good biocompatibility. Compared with the compound AmBF 3 -ES reported by our group previously [13] , the cytotoxicity of AmBF 3 -TEG-ES against MCF-7 and T47D cells showed no significant difference, indicating that the short PEG linker had almost no influence on the cytotoxicity of AmBF 3 -TEG-ES.
Radiosynthesis of [
18 F]AmBF 3 -TEG-ES. 18 F-labeling of the precursor AmBF 3 -TEG-ES was performed using the one- ∘ C, the RCY reached 61% and the RCP was over 98% after C18 purification ( Figure 5 ), but further increasing the reaction temperature did not produce a higher RCY. Therefore, the optimum radiolabeling condition (80 ∘ C, 30 min) was selected for further experiments. It was worth mentioning that the radiosynthesis process of the ER imaging agent was significantly simplified in comparison with that of 18 F-FES [16] [17] [18] . For the radiosynthesis of the widely studied ER imaging agent 18 F-FES, two reaction steps and semi-prep were required which resulted in a long synthesis time [16] [17] [18] . However, 18 Flabeling of the ER imaging agent through the one-step 18 F-19 F isotope exchange approach remarkably shortened the synthesis time and improved the radiolabeling efficiency, which obviated drying of fluoride-18 ion and HPLC purification with the total radiosynthesis time of 40 min. Moreover, the C18 column instead of HPLC purification also led to a high RCY with a satisfactory RCP. All the results indicated that the one-step 18 F-19 F isotope exchange could offer a more convenient method for the 18 F-labeling process and it was more suitable for clinical application.
In order to evaluate the stability of ∘ C. As shown in Figure 6 , the probe showed high stability (>95%) in PBS for up to 4 h. endow it with suitable pharmacokinetics in vivo for tumor imaging. Figure 7 (a), the cell uptake rate of [ 18 F]AmBF 3 -TEG-ES approached a plateau of ∼2.7% after incubation at 37 ∘ C for 60 min and remained at a similar uptake level to 120 min, indicating that the radiotracer could bind quickly to the ER + MCF-7 cells.
Similarly, approximately 2.8% cell uptake of [ 18 F]AmBF 3 -TEG-ES in T47D cells was determined at 60 min and almost no change up to 120 min, which was consistent with that of MCF-7 cell lines (Figure 7(b) ). For the blocking study, the cell uptake rate in MCF-7 cells decreased from 2.7% to 1.3% at presence of excess estradiol at 60 min, which decreased about 52% compared with the total cell uptake. In T47D cells, the cell uptake rate was only 1.2% at presence of excess estradiol at 60 min. These data showed that the cell uptake in ER + breast cancer cells could be effectively blocked by estradiol and further demonstrated the specificity of [
18 F]AmBF 3 -TEG-ES to ER.
Micro-PET Imaging.
In vivo micro-PET imaging was also carried out to investigate the specificity of 
Conclusions
In summary, a novel estradiol-based PET imaging agent [
18 F]AmBF 3 -TEG-ES was synthesized and characterized, and its in vitro and in vivo biological performance was also evaluated. The radiosynthesis of this compound was quite applicable in clinic by using the one-step 18 F-19 F isotope exchange reaction within 40 min, which obviated the drying of fluoride-18 ion and the HPLC purification. The high RCY, excellent RCP, good biocompatibility, high stability, and specific ER-targeting ability suggested that the radiotracer [ 18 F]AmBF3-TEG-ES might be a promising PET imaging agent for diagnosis of ER + breast cancers. 
